CoChat
Sign Up
Cited by 13Viral Infectious Diseases and Gene Expression in InsectsSARS-CoV-2 and COVID-19 ResearchTransgenic Plants and Applications

Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: A review

Open access
Azali, Muhammad Azharuddin, Mohamed, Salmah, Harun, Azian, Hussain, Faezahtul Arbaeyah, Shamsuddin, Shaharum, Johan, Muhammad Farid·2022·Journal of Genetic Engineering and Biotechnology
DOI 10.1186/s43141-022-00368-7PMC PMC9259773
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The baculovirus expression vector system has been developed for expressing a wide range of proteins, including enzymes, glycoproteins, recombinant viruses, and vaccines. The availability of the SARS-CoV-2 genome sequence has enabled the synthesis of SARS-CoV2 proteins in a baculovirus-insect cell platform for various applications. The most cloned SARS-CoV-2 protein is the spike protein, which plays a critical role in SARS-CoV-2 infection. It is available in its whole length or as subunits like S1 or the receptor-binding domain (RBD). Non-structural proteins (Nsps), another recombinant SARS-CoV-2 protein generated by the baculovirus expression vector system (BEV), are used in the identification of new medications or the repurposing of existing therapies for the treatment of COVID-19. Non-SARS-CoV-2 proteins generated by BEV for SARS-CoV-2 diagnosis or treatment include moloney murine leukemia virus reverse transcriptase (MMLVRT), angiotensin converting enzyme 2 (ACE2), therapeutic proteins, and recombinant antibodies. The recombinant proteins were modified to boost the yield or to stabilize the protein. CONCLUSION: This review covers the wide application of the recombinant protein produced using the baculovirus expression technology for COVID-19 research. A lot of improvements have been made to produce functional proteins with high yields. However, there is still room for improvement and there are parts of this field of research that have not been investigated yet.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s43141-022-00368-7

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BacMam is a modified baculovirus produced using Sf9 insect cells and pseudotyped to infect mammalian cells.

    “BacMam is a modified baculovirus produced using Sf9 insect cells and it is pseudotyped to infect mammalian cells [54,55,56].”

    From Effects of Mangiferin on LPS-Induced Inflammation and SARS-CoV-2 Viral Adsorption in Human Lung Cells (2022) · cites this paper as [54]

    The Diagnostic applications section says Sf9 cells are used to make recombinant baculovirus and describes a SARS-CoV-2-spike-pseudotyped baculovirus. It does not identify that virus as BacMam or say that BacMam is pseudotyped to infect mammalian cells (page not available in our copy). (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 132

  1. [1]van Oers MM Pijlman GP Vlak JM Thirty years of baculovirus-insect cell protein expression: from dark horse to mainstream technology J Gen Virol 2015 96 6 23 10.1099/vir.0.067108-0 25246703 · DOI
  2. [2]Felberbaum RS The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors Biotechnol J 2015 10 702 714 10.1002/biot.201400438 25800821 PMC7159335 · DOI
  3. [3]Pijlman GP Grose C Hick TAH Breukink HE van den Braak R Abbo SR Geertsema C van Oers MM Martens DE Esposito D Relocation of the attTn7 transgene insertion site in bacmid DNA enhances baculovirus genome stability and recombinant protein expression in insect cells Viruses 2020 12 1448 10.3390/v12121448 PMC7765880 33339324 · DOI
  4. [4]Hitchman RB Locanto E Possee RD King LA Optimizing the baculovirus expression vector system Methods 2011 55 52 57 10.1016/j.ymeth.2011.06.011 21945427 · DOI
  5. [5]Condreay JP Kost TA Baculovirus expression vectors for insect and mammalian cells Curr Drug Targets 2007 8 1126 1131 10.2174/138945007782151351 17979672 · DOI
  6. [6]Hitchman RB Possee RD Crombie AT Chambers A Ho K Siaterli E Lissina O Sternard H Novy R Loomis K Bird LE Owens RJ King LA Genetic modification of a baculovirus vector for increased expression in insect cells Cell Biol Toxicol 2010 26 57 68 10.1007/s10565-009-9133-y 19655260 · DOI
  7. [7]Finkelstein Y Faktor O Elroy-Stein O Levi BZ The use of bi-cistronic transfer vectors for the baculovirus expression system J Biotechnol 1999 75 33 44 10.1016/s0168-1656(99)00131-5 10510857 · DOI
  8. [8]Davies AH Jowett JBM Jones IM Recombinant baculovirus vectors expressing glutathione–S–transferase fusion proteins Nat Biotechnol 1993 11 933 936 10.1038/nbt0893-933 7763917 · DOI
  9. [9]Gong Z Jin Y Zhang Y Incorporation of partial polyhedrin homology sequences (PPHS) enhances the production of cloned foreign genes in a baculovirus expression system Biotechnol Appl Biochem 2006 43 165 170 10.1042/ba20050163 16313236 · DOI
  10. [10]Joshi PRH Venereo-Sanchez A Chahal PS Kamen AA Advancements in molecular design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-cell baculovirus expression platform Biotechnol J 2021 16 e2000021 10.1002/biot.202000021 33277815 · DOI
  11. [11]Ono C Okamoto T Abe T Matsuura Y Baculovirus as a tool for gene delivery and gene therapy Viruses 2018 10 510 10.3390/v10090510 PMC6164903 30235841 · DOI
  12. [12]Martínez-Solís M Herrero S Targovnik AM Engineering of the baculovirus expression system for optimized protein production Appl Microbiol Biotechnol 2019 103 113 123 10.1007/s00253-018-9474-7 30374673 · DOI
  13. [13]van Oers MM Opportunities and challenges for the baculovirus expression system J Invertebr Pathol 2011 107 S3 S15 10.1016/j.jip.2011.05.001 21784228 · DOI
  14. [14]Khurana A Allawadhi P Khurana I Allwadhi S Weiskirchen R Banothu AK Chhabra D Joshi K Bharani KK Role of nanotechnology behind the success of mRNA vaccines for COVID-19 Nano Today 2021 38 101142 10.1016/j.nantod.2021.101142 33815564 PMC7997390 · DOI
  15. [15]Takahashi M Tehseen M Salunke R Takahashi E Mfarrej S Sobhy MA Alhamlan FS Hala S Ramos-Mandujano G Al-Qahtani AA Alofi FS Alsomali A Hashem AM Khogeer A Almontashiri NAM Lee JM Mon H Sakashita K Li M Kusakabe T Pain A Hamdan SM Quick and easy Assembly of a one-step qRT-PCR kit for COVID-19 diagnostics using in-house enzymes ACS Omega 2021 6 7374 7386 10.1021/acsomega.0c05635 33778250 PMC7986002 · DOI
  16. [16]Amanat F Strohmeier S Rathnasinghe R Schotsaert M Coughlan L García-Sastre A Krammer F Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model mBio 2021 12 e02648 e02620 10.1128/mBio.02648-20 33653892 PMC8092267 · DOI
  17. [17]Shetti NP Mishra A Bukkitgar SD Basu S Narang J Raghava Reddy K Aminabhavi TM Conventional and nanotechnology-based sensing methods for SARS coronavirus (2019-nCoV) ACS Appl Bio Mater 2021 4 1178 1190 10.1021/acsabm.0c01545 34192244 · DOI
  18. [18]Huang Y Yang C Xu X-f Xu W Liu S-w Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Acta Pharmacol Sin 2020 41 1141 1149 10.1038/s41401-020-0485-4 32747721 PMC7396720 · DOI
  19. [19]Samrat SK Tharappel AM Li Z Li H Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development Virus Res 2020 288 198141 10.1016/j.virusres.2020.198141 32846196 PMC7443330 · DOI
  20. [20]Li T Zheng Q Yu H Wu D Xue W Xiong H Huang X Nie M Yue M Rong R Zhang S Zhang Y Wu Y Wang S Zha Z Chen T Deng T Wang Y Zhang T Chen Y Yuan Q Zhao Q Zhang J Gu Y Li S Xia N SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates Emerg Microbes Infect 2020 9 2076 2090 10.1080/22221751.2020.1821583 32897177 PMC7534368 · DOI
  21. [21]Zhang Y Zhao W Mao Y Chen Y Wang S Zhong Y Su T Gong M Du D Lu X Cheng J Yang H Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins Mol Cell Proteomics 2021 20 100058 10.1074/mcp.ra120.002295 33077685 PMC7876485 · DOI
  22. [22]Wang Y Wu Z Hu W Hao P Yang S Impact of expressing cells on glycosylation and glycan of the SARS-CoV-2 spike glycoprotein ACS Omega 2021 6 15988 15999 10.1021/acsomega.1c01785 34179644 PMC8204757 · DOI
  23. [23]Huang C Tan Z Zhao K Zou W Wang H Gao H Sun S Bu D Chai W Li Y The effect of N-glycosylation of SARS-CoV-2 spike protein on the virus interaction with the host cell ACE2 receptor iScience 2021 24 103272 10.1016/j.isci.2021.103272 34661088 PMC8513389 · DOI
  24. [24]Fujita R Hino M Ebihara T Nagasato T Masuda A Lee JM Fujii T Mon H Kakino K Nagai R Tanaka M Tonooka Y Moriyama T Kusakabe T Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system Biochem Biophys Res Commun 2020 529 257 262 10.1016/j.bbrc.2020.06.020 32703420 PMC7280120 · DOI
  25. [25]Xiong X Qu K Ciazynska KA Hosmillo M Carter AP Ebrahimi S Ke Z Scheres SHW Bergamaschi L Grice GL Zhang Y Bradley J Lyons PA Smith KGC Toshner M Elmer A Ribeiro C Kourampa J Jose S Kennet J Rowlands J Meadows A O’Brien C Rastall R Crucusio C Hewitt S Price J Calder J Canna L Bucke A Tordesillas H Harris J Ruffolo V Domingo J Graves B Butcher H Caputo D Le Gresley E Dunmore BJ Martin J Legchenko E Treacy C Huang C Wood J Sutcliffe R Hodgson J Shih J Graf S Tong Z Mescia F Tilly T O’Donnell C Hunter K Pointon L Pond N Wylot M Jones E Fawke S Bullman B Turner L Jarvis I Omarjee O De Sa A Marsden J Betancourt A Perera M Epping M Richoz N Bower G Sharma R Nice F Huhn O Stark H Walker N Stirrups K Ovington N Dewhust E Li E Papadia S Nathan JA Baker S James LC Baxendale HE Goodfellow I Doffinger R Briggs JAG The C-NC-BC A thermostable, closed SARS-CoV-2 spike protein trimer Nat Struct Mol Biol 2020 27 934 941 10.1038/s41594-020-0478-5 32737467 PMC7116388 · DOI · Paper page
  26. [26]Wang HJ, Xiang YH, Hu R, Ji R, Wang YP (2021) Research progress in laboratory detection of SARS-CoV-2. Ir J Med Sci:1-9. 10.1007/s11845-021-02604-4 PMC7990494 33763777 · DOI
  27. [27]Amanat F Stadlbauer D Strohmeier S Nguyen THO Chromikova V McMahon M Jiang K Arunkumar GA Jurczyszak D Polanco J Bermudez-Gonzalez M Kleiner G Aydillo T Miorin L Fierer DS Lugo LA Kojic EM Stoever J Liu STH Cunningham-Rundles C Felgner PL Moran T García-Sastre A Caplivski D Cheng AC Kedzierska K Vapalahti O Hepojoki JM Simon V Krammer F A serological assay to detect SARS-CoV-2 seroconversion in humans Nat Med 2020 26 1033 1036 10.1038/s41591-020-0913-5 32398876 PMC8183627 · DOI · Paper page
  28. [28]Smith I Mc Callum GJ Sabljic AV Marfia JI Bombicino SS Trabucchi A Iacono RF Birenbaum JM Vazquez SC Minoia JM Cascone O López MG Taboga O Targovnik AM Wolman FJ Fingermann M Alonso LG Valdez SN Miranda MV Rapid and cost-effective process based on insect larvae for scale-up production of SARS-COV-2 spike protein for serological COVID-19 testing Biotechnol Bioeng 2021 118 4129 4137 10.1002/bit.27889 34264519 PMC8426952 · DOI
  29. [29]Jégouic SM, Jones IM, Edwards AD (2021) Affordable mobile microfluidic diagnostics: minimum requirements for smartphones and digital imaging for colorimetric and fluorometric anti-dengue and anti-SARS-CoV-2 antibody detection. Wellcome Open Res 6. 10.12688/wellcomeopenres.16628.1 PMC9614285 36312459 · DOI
  30. [30]Jegouic SM, Loureiro S, Thom M, Paliwal D, Jones IM (2020) Recombinant SARS-CoV-2 spike proteins for sero-surveillance and epitope mapping. bioRxiv. 10.1101/2020.05.21.109298 · DOI
  31. [31]Klausberger M Duerkop M Haslacher H Wozniak-Knopp G Cserjan-Puschmann M Perkmann T Lingg N Aguilar PP Laurent E De Vos J Hofner M Holzer B Stadler M Manhart G Vierlinger K Egger M Milchram L Gludovacz E Marx N Köppl C Tauer C Beck J Maresch D Grünwald-Gruber C Strobl F Satzer P Stadlmayr G Vavra U Huber J Wahrmann M Eskandary F Breyer M-K Sieghart D Quehenberger P Leitner G Strassl R Egger AE Irsara C Griesmacher A Hoermann G Weiss G Bellmann-Weiler R Loeffler-Ragg J Borth N Strasser R Jungbauer A Hahn R Mairhofer J Hartmann B Binder NB Striedner G Mach L Weinhäusel A Dieplinger B Grebien F Gerner W Binder CJ Grabherr R A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests eBioMedicine 2021 67 103348 10.1016/j.ebiom.2021.103348 33906067 PMC8099623 · DOI
  32. [32]Wang J Li D Zhou Q Wiltse A Zand MS Antibody mediated immunity to SARS-CoV-2 and human coronaviruses: multiplex beads assay and volumetric absorptive microsampling to generate immune repertoire cartography Front Immunol 2021 12 696370 10.3389/fimmu.2021.696370 34386006 PMC8353270 · DOI
  33. [33]Indenbaum V Koren R Katz-Likvornik S Yitzchaki M Halpern O Regev-Yochay G Cohen C Biber A Feferman T Cohen Saban N Dhan R Levin T Gozlan Y Weil M Mor O Mandelboim M Sofer D Mendelson E Lustig Y Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis PLoS ONE 2020 15 e0241164 10.1371/journal.pone.0241164 33227020 PMC7682882 · DOI
  34. [34]Hoffman T Kolstad L Lindahl JF Albinsson B Bergqvist A Rönnberg B Lundkvist Å Diagnostic potential of a luminex-based coronavirus disease 2019 suspension immunoassay (COVID-19 SIA) for the detection of antibodies against SARS-CoV-2 Viruses 2021 13 993 10.3390/v13060993 34073484 PMC8227055 · DOI
  35. [35]Wilde M Klausberger M Palmberger D Ernst W Grabherr R Tnao38, high five and Sf9--evaluation of host-virus interactions in three different insect cell lines: baculovirus production and recombinant protein expression Biotechnol Lett 2014 36 743 749 10.1007/s10529-013-1429-6 24375231 PMC3955137 · DOI
  36. [36]de Camargo BR da Silva LA de Oliveira AS Ribeiro BM An easy pipeline for one-step purification of SARS-CoV-2 nucleocapsid protein from insect cell suspension culture J Virol Methods 2021 299 114341 10.1016/j.jviromet.2021.114341 34699776 PMC8539556 · DOI
  37. [37]Pramanik A Gao Y Patibandla S Mitra D McCandless MG Fassero LA Gates K Tandon R Chandra Ray P The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles Nanoscale Adv 2021 3 1588 1596 10.1039/d0na01007c 34381960 PMC8323809 · DOI
  38. [38]Lopandić Z Protić-Rosić I Todorović A Glamočlija S Gnjatović M Ćujic D Gavrović-Jankulović M IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein Int J Mol Sci 2021 22 4951 10.3390/ijms22094951 34066920 PMC8125631 · DOI
  39. [39]Lu L Chu AW-H Zhang RR Chan W-M Ip JD Tsoi H-W Chen L-l Cai J-P Lung DC Tam AR Yau Y-S Kwan MY-W To W-K Tsang OT-Y Lee LL-Y Yi H Ip T-C Poon RW-S Siu GK-H Mok BW-Y Cheng VC-C Chan KH Yuen K-Y Hung IF-N To KK-W The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum EBioMedicine 2021 71 103544 10.1016/j.ebiom.2021.103544 34419925 PMC8374549 · DOI
  40. [40]Singh V Allawadhi P Khurana A Banothu AK Bharani KK Critical neurological features of COVID-19: Role of imaging methods and biosensors for effective diagnosis Sensors Intern 2021 2 100098 100098 10.1016/j.sintl.2021.100098 PMC8117537 34766055 · DOI
  41. [41]Hajian R Balderston S Tran T deBoer T Etienne J Sandhu M Wauford NA Chung J-Y Nokes J Athaiya M Paredes J Peytavi R Goldsmith B Murthy N Conboy IM Aran K Detection of unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect transistor Nat Biomed Eng 2019 3 427 437 10.1038/s41551-019-0371-x 31097816 PMC6556128 · DOI
  42. [42]Mahari S Roberts A Shahdeo D Gandhi S eCovSens-ultrasensitive novel in-house built printed circuit board based electrochemical device for rapid detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2 BioRxiv 2020 2020 04 24.059204 10.1101/2020.04.24.059204 · DOI
  43. [43]Mavrikou S Moschopoulou G Tsekouras V Kintzios S Development of a portable, ultra-rapid and ultra-sensitive cell-based biosensor for the direct detection of the SARS-CoV-2 S1 spike protein antigen Sensors 2020 20 3121 10.3390/s20113121 PMC7309076 32486477 · DOI
  44. [44]Zhao Z Cui H Song W Ru X Zhou W Yu X A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2 BioRxiv 2020 2020 02 22.961268 10.1101/2020.02.22.961268 · DOI
  45. [45]Moitra P Alafeef M Dighe K Frieman MB Pan D Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles ACS Nano 2020 14 7617 7627 10.1021/acsnano.0c03822 32437124 PMC7263075 · DOI
  46. [46]Huang Z Tian D Liu Y Lin Z Lyon CJ Lai W Fusco D Drouin A Yin X Hu T Ning B Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis Biosensors and Bioelectronics 2020 164 112316 10.1016/j.bios.2020.112316 32553350 PMC7245202 · DOI
  47. [47]Qiu G Gai Z Tao Y Schmitt J Kullak-Ublick GA Wang J Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection ACS Nano 2020 14 5268 5277 10.1021/acsnano.0c02439 32281785 · DOI
  48. [48]Li Z Yi Y Luo X Xiong N Liu Y Li S Sun R Wang Y Hu B Chen W Zhang Y Wang J Huang B Lin Y Yang J Cai W Wang X Cheng J Chen Z Sun K Pan W Zhan Z Chen L Ye F Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis J Med Virol 2020 92 1518 1524 10.1002/jmv.25727 32104917 PMC7228300 · DOI
  49. [49]Tian B Gao F Fock J Dufva M Hansen MF Homogeneous circle-to-circle amplification for real-time optomagnetic detection of SARS-CoV-2 RdRp coding sequence Biosensors and Bioelectronics 2020 165 112356 10.1016/j.bios.2020.112356 32510339 · DOI
  50. [50]Pollet J Chen W-H Strych U Recombinant protein vaccines, a proven approach against coronavirus pandemics Adv Drug Deliv Rev 2021 170 71 82 10.1016/j.addr.2021.01.001 33421475 PMC7788321 · DOI
  51. [51]Yan Y Pang Y Lyu Z Wang R Wu X You C Zhao H Manickam S Lester E Wu T Pang CH The COVID-19 vaccines: recent development, challenges and prospects Vaccines (Basel) 2021 9 349 10.3390/vaccines9040349 33916489 PMC8067284 · DOI
  52. [52]Guruprasad L Human SARS CoV-2 spike protein mutations Proteins 2021 89 569 576 10.1002/prot.26042 33423311 PMC8014176 · DOI
  53. [53]Francica JR Flynn BJ Foulds KE Noe AT Werner AP Moore IN Gagne M Johnston TS Tucker C Davis RL Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates Sci Transl Med 2021 13 eabi4547 10.1126/scitranslmed.abi4547 34315825 PMC9266840 · DOI
  54. [54]Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon A-L, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera MDM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet M-H, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S (2021) Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study. medRxiv. 10.1101/2021.10.08.21264302 · DOI
  55. [55]Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Morre IN, Gagne M, Johnston TS, Tucker C, Davis RL (2021) Vaccination with SARS-CoV-2 spike protein and AS03 adjuvant induces rapid anamnestic antibodies in the lung and protects against virus challenge in nonhuman primates. bioRxiv. 10.1101/2021.03.02.433390 · DOI
  56. [56]Liu X, Song H, Jiang J, Gao X, Yi Y, Shang Y, Li J, Li D, Zeng Z, Li Y (2021) Self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induces protective immunity in mice. bioRxiv. 10.1101/2021.02.05.428685 PMC10038678 37007452 · DOI
  57. [57]Chen S Evert B Adeniyi A Salla-Martret M Lua LHL Ozberk V Pandey M Good MF Suhrbier A Halfmann P Kawaoka Y Rehm BHA Ambient temperature stable, scalable COVID-19 polymer particle vaccines induce protective immunity Adv Healthc Mater 2021 11 e2102089 10.1002/adhm.202102089 34716678 PMC8652985 · DOI
  58. [58]Chevillard C, Amen A, Besson S, Hannani D, Bally I, Dettling V, Gout E, Moreau CJ, Buisson M, Gallet S (2021) Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization using a versatile adenovirus-inspired multimerization platform. bioRxiv. 10.1101/2021.09.13.460076 PMC8828441 35151843 · DOI
  59. [59]Tamminen K Heinimäki S Gröhn S Blazevic V Fusion protein of rotavirus VP6 and SARS-CoV-2 receptor binding domain induces T cell responses Vaccines (Basel) 2021 9 733 10.3390/vaccines9070733 34358149 PMC8309989 · DOI
  60. [60]Cho H Jang Y Park KH Choi H Nowakowska A Lee HJ Kim M Kang MH Kim JH Shin HY Oh YK Kim YB Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 NPJ Vaccines 2021 6 37 10.1038/s41541-021-00303-w 33741992 PMC7979866 · DOI
  61. [61]Mi Y Xie T Zhu B Tan J Li X Luo Y Li F Niu H Han J Lv W Wang J Production of SARS-CoV-2 Virus-Like Particles in Insect Cells Vaccines (Basel) 2021 9 554 10.3390/vaccines9060554 34073159 PMC8227081 · DOI
  62. [62]Chu K Kang H Yoon K Lee H Moon E Han B Quan F Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 S glycoprotein, S1, or S2 domains Vaccine (Bassel) 2021 9 920 10.3390/vaccines9080920 PMC8402567 34452044 · DOI
  63. [63]van Oosten L Altenburg JJ Fougeroux C Geertsema C van den End F Evers WAC Westphal AH Lindhoud S van den Berg W Swarts DC Deurhof L Suhrbier A Le TT Torres Morales S Myeni SK Kikkert M Sander AF de Jongh WA Dagil R Nielsen MA Salanti A Søgaard M Keijzer TMP Weijers D Eppink MHM Wijffels RH van Oers MM Martens DE Pijlman GP Two-component nanoparticle vaccine displaying glycosylated Spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants mBio 2021 12 e0181321 10.1128/mBio.01813-21 34634927 PMC8510518 · DOI
  64. [64]Dai L Zheng T Xu K Han Y Xu L Huang E An Y Cheng Y Li S Liu M Yang M Li Y Cheng H Yuan Y Zhang W Ke C Wong G Qi J Qin C Yan J Gao GF A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS Cell 2020 182 722 733.e11 10.1016/j.cell.2020.06.035 32645327 PMC7321023 · DOI
  65. [65]Tabynov K, Turebekov N, Babayeva M, Fomin G, Yerubaev T, Yespolov T, Li L, Renukaradhya G, Petrovsky N, Tabynov K (2021) An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. Res Square. 10.21203/rs.3.rs-902649/v1 PMC8866462 35197485 · DOI
  66. [66]Li L Honda-Okubo Y Huang Y Jang H Carlock MA Baldwin J Piplani S Bebin-Blackwell AG Forgacs D Sakamoto K Stella A Turville S Chataway T Colella A Triccas J Ross TM Petrovsky N Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection Vaccine 2021 39 5940 5953 10.1016/j.vaccine.2021.07.087 34420786 PMC8328570 · DOI
  67. [67]Sekimukai H Iwata-Yoshikawa N Fukushi S Tani H Kataoka M Suzuki T Hasegawa H Niikura K Arai K Nagata N Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs Microbiol Immunol 2020 64 33 51 10.1111/1348-0421.12754 31692019 PMC7168429 · DOI
  68. [68]Pavot V, Berry C, Kishko M, Anosova NG, Huang D, Tibbitts T, Raillard A, Gautheron S, Gutzeit C, Koutsoukos M (2021) SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. bioRxiv. 10.1101/2021.09.20.461023 · DOI
  69. [69]Li J Ulitzky L Silberstein E Taylor DR Viscidi R Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates Viral Immunol 2013 26 126 132 10.1089/vim.2012.0076 23573979 PMC3624630 · DOI
  70. [70]Kanekiyo M Wei C-J Yassine HM McTamney PM Boyington JC Whittle JRR Rao SS Kong W-P Wang L Nabel GJ Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Nature 2013 499 102 106 10.1038/nature12202 23698367 PMC8312026 · DOI
  71. [71]Yang J Wang W Chen Z Lu S Yang F Bi Z Bao L Mo F Li X Huang Y Hong W Yang Y Zhao Y Ye F Lin S Deng W Chen H Lei H Zhang Z Luo M Gao H Zheng Y Gong Y Jiang X Xu Y Lv Q Li D Wang M Li F Wang S Wang G Yu P Qu Y Yang L Deng H Tong A Li J Wang Z Shen G Zhao Z Li Y Luo J Liu H Yu W Yang M Xu J Wang J Li H Wang H Kuang D Lin P Hu Z Guo W Cheng W He Y Song X Chen C Xue Z Yao S Chen L Ma X Chen S Gou M Huang W Wang Y Fan C Tian Z Shi M Wang FS Dai L Wu M Li G Peng Y Qian Z Huang C Lau JYN Yang Z Wei Y Cen X Peng X Qin C Zhang K Lu G Wei X A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity Nature 2020 586 572 577 10.1038/s41586-020-2599-8 32726802 · DOI
  72. [72]Lin H-T, Chen C-C, Chiao D-J, Chang T-Y, Chen X-A, Young J-J, Kuo S-C (2021) Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. Int J Biol Macromol. 10.1016/j.ijbiomac.2021.11.020 PMC8580573 34774590 · DOI
  73. [73]Lee HJ Park N Cho HJ Yoon JK Van ND Oh YK Kim YB Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1 Vaccine 2010 28 1613 1619 10.1016/j.vaccine.2009.11.044 19961961 · DOI
  74. [74]Kost TA Condreay JP Jarvis DL Baculovirus as versatile vectors for protein expression in insect and mammalian cells Nat Biotechnol 2005 23 567 575 10.1038/nbt1095 15877075 PMC3610534 · DOI · Paper page
  75. [75]Contreras-Gómez A Sánchez-Mirón A García-Camacho F Molina-Grima E Chisti Y Protein production using the baculovirus-insect cell expression system Biotechnol Prog 2014 30 1 18 10.1002/btpr.1842 24265112 · DOI
  76. [77]Heath PT Galiza EP Baxter DN Boffito M Browne D Burns F Chadwick DR Clark R Cosgrove C Galloway J Goodman AL Heer A Higham A Iyengar S Jamal A Jeanes C Kalra PA Kyriakidou C McAuley DF Meyrick A Minassian AM Minton J Moore P Munsoor I Nicholls H Osanlou O Packham J Pretswell CH San Francisco Ramos A Saralaya D Sheridan RP Smith R Soiza RL Swift PA Thomson EC Turner J Viljoen ME Albert G Cho I Dubovsky F Glenn G Rivers J Robertson A Smith K Toback S Safety and efficacy of NVX-CoV2373 Covid-19 vaccine N Engl J Med 2021 385 1172 1183 10.1056/NEJMoa2107659 34192426 PMC8262625 · DOI · Paper page
  77. [78]Forchette L Sebastian W Liu T A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics Curr Med Sci 2021 41 1037 1051 10.1007/s11596-021-2395-1 34241776 PMC8267225 · DOI
  78. [79]Callaway E Omicron likely to weaken COVID vaccine protection Nature 2021 600 367 368 10.1038/d41586-021-03672-3 34880488 · DOI
  79. [80]Zhang J He Q An C Mao Q Gao F Bian L Wu X Wang Q Liu P Song L Huo Y Liu S Yan X Yang J Cui B Li C Wang J Liang Z Xu M Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine Emerg Microbes Infect 2021 10 1598 1608 10.1080/22221751.2021.1957401 34278956 PMC8381941 · DOI
  80. [81]Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y (2022) Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. medRxiv. 10.1101/2022.03.01.22271735 PMC9393164 36031500 · DOI
  81. [82]Aledo-Serrano A Gil-Nagel A Isla J Mingorance A Mendez-Hermida F Hernandez-Alcoceba R Gene therapies and COVID-19 vaccines: a necessary discussion in relation with viral vector-based approaches Orphanet J Rare Dis 2021 16 316 10.1186/s13023-021-01958-3 34271959 PMC8284696 · DOI
  82. [83]Nasuelli NA De Marchi F Cecchin M De Paoli I Onorato S Pettinaroli R Savoini G Godi L A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine Neurol Sci 2021 42 4747 4749 10.1007/s10072-021-05467-w 34272622 PMC8285283 · DOI
  83. [84]Baral PK Yin J James MNG Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2 Int J Biol Macromol 2021 186 490 500 10.1016/j.ijbiomac.2021.07.013 34237371 PMC8256663 · DOI
  84. [86]Liu H Wu NC Yuan M Bangaru S Torres JL Caniels TG van Schooten J Zhu X Lee C-CD Brouwer PJM van Gils MJ Sanders RW Ward AB Wilson IA Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity Immunity 2020 53 1272 1280.e5 10.1016/j.immuni.2020.10.023 33242394 PMC7687367 · DOI
  85. [87]Ullah I Prévost J Ladinsky MS Stone H Lu M Anand SP Beaudoin-Bussières G Symmes K Benlarbi M Ding S Gasser R Fink C Chen Y Tauzin A Goyette G Bourassa C Medjahed H Mack M Chung K Wilen CB Dekaban GA Dikeakos JD Bruce EA Kaufmann DE Stamatatos L McGuire AT Richard J Pazgier M Bjorkman PJ Mothes W Finzi A Kumar P Uchil PD Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy Immunity 2021 54 2143 2158.e15 10.1016/j.immuni.2021.08.015 34453881 PMC8372518 · DOI
  86. [88]Zhou Y Liu Z Li S Xu W Zhang Q Silva IT Li C Wu Y Jiang Q Liu Z Wang Q Guo Y Wu J Gu C Cai X Qu D Mayer CT Wang X Jiang S Ying T Yuan Z Xie Y Wen Y Lu L Wang Q Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD Cell Rep 2021 34 108699 10.1016/j.celrep.2021.108699 33485405 PMC7802522 · DOI
  87. [89]Zhou X Ma F Xie J Yuan M Li Y Shaabani N Zhao F Huang D Wu NC Lee C-CD Liu H Li J Chen Z Hong Y Liu W-H Xiao N Burton DR Tu H Li H Chen X Teijaro JR Wilson IA Xiao C Huang Z Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2 Cell Rep 2021 35 109109 10.1016/j.celrep.2021.109109 33932326 PMC8064889 · DOI
  88. [90]Du S Cao Y Zhu Q Yu P Qi F Wang G Du X Bao L Deng W Zhu H Liu J Nie J Zheng Y Liang H Liu R Gong S Xu H Yisimayi A Lv Q Wang B He R Han Y Zhao W Bai Y Qu Y Gao X Ji C Wang Q Gao N Huang W Wang Y Xie XS Su X-d Xiao J Qin C Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy Cell 2020 183 1013 1023.e13 10.1016/j.cell.2020.09.035 32970990 PMC7489885 · DOI
  89. [91]Cao Y Su B Guo X Sun W Deng Y Bao L Zhu Q Zhang X Zheng Y Geng C Chai X He R Li X Lv Q Zhu H Deng W Xu Y Wang Y Qiao L Tan Y Song L Wang G Du X Gao N Liu J Xiao J Su X-d Du Z Feng Y Qin C Qin C Jin R Xie XS Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells Cell 2020 182 73 84.e16 10.1016/j.cell.2020.05.025 32425270 PMC7231725 · DOI · Paper page
  90. [92]Bertoglio F Fühner V Ruschig M Heine PA Abassi L Klünemann T Rand U Meier D Langreder N Steinke S Ballmann R Schneider KT Roth KDR Kuhn P Riese P Schäckermann D Korn J Koch A Chaudhry MZ Eschke K Kim Y Zock-Emmenthal S Becker M Scholz M Moreira GMSG Wenzel EV Russo G Garritsen HSP Casu S Gerstner A Roth G Adler J Trimpert J Hermann A Schirrmann T Dübel S Frenzel A Van den Heuvel J Čičin-Šain L Schubert M Hust M A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations Cell Rep 2021 36 109433 10.1016/j.celrep.2021.109433 34273271 PMC8260561 · DOI
  91. [93]Liu H Yuan M Huang D Bangaru S Zhao F Lee C-CD Peng L Barman S Zhu X Nemazee D Burton DR van Gils MJ Sanders RW Kornau H-C Reincke SM Prüss H Kreye J Wu NC Ward AB Wilson IA A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection Cell Host Microbe 2021 29 806 818.e6 10.1016/j.chom.2021.04.005 33894127 PMC8049401 · DOI
  92. [94]Korn J Schäckermann D Kirmann T Bertoglio F Steinke S Heisig J Ruschig M Rojas G Langreder N Wenzel EV Roth KDR Becker M Meier D van den Heuvel J Hust M Dübel S Schubert M Baculovirus-free insect cell expression system for high yield antibody and antigen production Sci Rep 2020 10 21393 10.1038/s41598-020-78425-9 33288836 PMC7721901 · DOI
  93. [95]Ebihara T Masuda A Takahashi D Hino M Mon H Kakino K Fujii T Fujita R Ueda T Lee JM Production of scFv, Fab, and IgG of CR3022 antibodies against SARS-CoV-2 using silkworm-baculovirus expression system Mol Biotechnol 2021 63 1223 1234 10.1007/s12033-021-00373-0 34304364 PMC8310559 · DOI
  94. [96]Miller A Leach A Thomas J McAndrew C Bentley E Mattiuzzo G John L Mirazimi A Harris G Gamage N A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection Sci Rep 2021 11 1 13 10.1038/s41598-021-89957-z 34012108 PMC8134500 · DOI
  95. [97]Liu Z, Wu H, Egland KA, Gilliland TC, Dunn MD, Luke TC, Sullivan EJ, Klimstra WB, Bausch CL, Whelan SP (2021) Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum Vaccin Immunother. 10.1080/21645515.2021.1940652 PMC8290372 34228597 · DOI
  96. [98]Wei S, Duan S, Liu X, Wang H, Ding S, Chen Y, Xie J, Tian J, Yu N, Ge p, Zhang x, chen X, Li Y, Meng Q (2021) Chicken egg yolk antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. Int Immunopharmacol 90:107172. doi:10.1016/j.intimp.2020.107172. PMC7608017 33191178 · DOI
  97. [99]Shi R Shan C Duan X Chen Z Liu P Song J Song T Bi X Han C Wu L A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Nature 2020 584 120 124 10.1038/s41586-020-2381-y 32454512 · DOI · Paper page
  98. [100]Moriwaki T Abe S Oshimura M Kazuki Y Transchromosomic technology for genomically humanized animals Exp Cell Res 2020 390 111914 10.1016/j.yexcr.2020.111914 32142854 · DOI
  99. [101]Brüggemann M Osborn MJ Ma B Hayre J Avis S Lundstrom B Buelow R Human antibody production in transgenic animals Arch Immunol Ther Exp (Warsz) 2015 63 101 108 10.1007/s00005-014-0322-x 25467949 PMC4359279 · DOI
  100. [102]Lv Z Deng Y-Q Ye Q Cao L Sun C-Y Fan C Huang W Sun S Sun Y Zhu L Chen Q Wang N Nie J Cui Z Zhu D Shaw N Li X-F Li Q Xie L Wang Y Rao Z Qin C-F Wang X Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody Science 2020 369 1505 1509 10.1126/science.abc5881 32703908 PMC7402622 · DOI
  101. [103]Piccoli L Park YJ Tortorici MA Czudnochowski N Walls AC Beltramello M Silacci-Fregni C Pinto D Rosen LE Bowen JE Acton OJ Jaconi S Guarino B Minola A Zatta F Sprugasci N Bassi J Peter A De Marco A Nix JC Mele F Jovic S Rodriguez BF Gupta SV Jin F Piumatti G Lo Presti G Pellanda AF Biggiogero M Tarkowski M Pizzuto MS Cameroni E Havenar-Daughton C Smithey M Hong D Lepori V Albanese E Ceschi A Bernasconi E Elzi L Ferrari P Garzoni C Riva A Snell G Sallusto F Fink K Virgin HW Lanzavecchia A Corti D Veesler D Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology Cell 2020 183 1024 1042 e21 10.1016/j.cell.2020.09.037 32991844 PMC7494283 · DOI · Paper page
  102. [104]Yuan M Wu NC Zhu X Lee CD So RTY Lv H Mok CKP Wilson IA A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV Science 2020 368 630 633 10.1126/science.abb7269 32245784 PMC7164391 · DOI
  103. [105]Zhou H Chen Y Zhang S Niu P Qin K Jia W Huang B Zhang S Lan J Zhang L Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein Nat Commun 2019 10 1 13 10.1038/s41467-019-10897-4 31296843 PMC6624210 · DOI
  104. [106]Lu Q Zhang Z Li H Zhong K Zhao Q Wang Z Wu Z Yang D Sun S Yang N Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein J Nanobiotechnology 2021 19 1 12 10.1186/s12951-021-00768-w 33514385 PMC7844813 · DOI
  105. [107]Nieto GV Jara R Watterson D Modhiran N Amarilla AA Himelreichs J Khromykh AA Salinas-Rebolledo C Pinto T Cheuquemilla Y Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody Sci Rep 2021 11 1 14 10.1038/s41598-021-82833-w 33558635 PMC7870875 · DOI
  106. [108]Haschke M Schuster M Poglitsch M Loibner H Salzberg M Bruggisser M Penninger J Krähenbühl S Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects Clin Pharmacokinet 2013 52 783 792 10.1007/s40262-013-0072-7 23681967 · DOI
  107. [109]Khan A Benthin C Zeno B Albertson TE Boyd J Christie JD Hall R Poirier G Ronco JJ Tidswell M Hardes K Powley WM Wright TJ Siederer SK Fairman DA Lipson DA Bayliffe AI Lazaar AL A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome Crit Care 2017 21 234 10.1186/s13054-017-1823-x 28877748 PMC5588692 · DOI
  108. [110]Ye F Lin X Chen Z Yang F Lin S Yang J Chen H Sun H Wang L Wen A Zhang X Dai Y Cao Y Shen G Yang L Li J Wang Z Wang W Wei X Lu G S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis Signal Transduct Target Ther 2021 6 343 10.1038/s41392-021-00756-4 34531369 PMC8444507 · DOI
  109. [111]Shu B Gong P Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation Proc Natl Acad Sci USA 2016 113 E4005 10.1073/pnas.1602591113 27339134 PMC4948327 · DOI
  110. [112]Ahmad J Ikram S Ahmad F Rehman IU Mushtaq M SARS-CoV-2 RNA dependent RNA polymerase (RdRp) - a drug repurposing study Heliyon 2020 6 e04502 10.1016/j.heliyon.2020.e04502 32754651 PMC7377705 · DOI
  111. [113]Wang M, Ye F, Su J, Zhao J, Yuan B, Huang B, Peng Q, Peng R, Sun Y, Bai S (2020) Caspofungin and LTX-315 inhibit SARS-CoV-2 replication by targeting the nsp12 polymerase. Res Square. 10.21203/rs.3.rs-19872/v1 · DOI
  112. [114]Ren P-X, Shang W-J, Yin W-C, Ge H, Wang L, Zhang X-L, Li B-Q, Li H-L, Xu Y-C, Xu EH (2021) A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta Pharmacol Sin:1–11. 10.1038/s41401-021-00668-7 PMC8076879 33907306 · DOI
  113. [115]Toelzer C Gupta K Yadav SKN Borucu U Davidson AD Williamson MK Shoemark DK Garzoni F Staufer O Milligan R Capin J Mulholland AJ Spatz J Fitzgerald D Berger I Schaffitzel C Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein Science 2020 370 725 730 10.1126/science.abd3255 32958580 PMC8050947 · DOI
  114. [116]Gordon CJ Tchesnokov EP Woolner E Perry JK Feng JY Porter DP Götte M Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency J Biol Chem 2020 295 6785 6797 10.1074/jbc.RA120.013679 32284326 PMC7242698 · DOI
  115. [117]Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q (2020) Structural basis for repurpose and design of nucleoside drugs for treating COVID-19. bioRxiv. 10.1101/2020.11.01.363812 · DOI
  116. [118]Bertolin AP Weissmann F Zeng J Posse V Milligan JC Canal B Ulferts R Wu M Drury LS Howell M Beale R Diffley JFX Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase Biochem J 2021 478 2425 2443 10.1042/bcj20210200 34198323 PMC8286815 · DOI
  117. [119]Naydenova K Muir KW Wu LF Zhang Z Coscia F Peet MJ Castro-Hartmann P Qian P Sader K Dent K Kimanius D Sutherland JD Löwe J Barford D Russo CJ Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP Proc Natl Acad Sci USA 2021 118 e2021946118 10.1073/pnas.2021946118 33526596 PMC7896311 · DOI
  118. [120]Yin W Luan X Li Z Zhou Z Wang Q Gao M Wang X Zhou F Shi J You E Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin Nat Struct Mol Biol 2021 28 319 325 10.1038/s41594-021-00570-0 33674802 · DOI
  119. [121]Gordon CJ Tchesnokov EP Schinazi RF Götte M Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template J Biol Chem 2021 297 100770 10.1016/j.jbc.2021.100770 33989635 PMC8110631 · DOI
  120. [122]Canal B McClure AW Curran JF Wu M Ulferts R Weissmann F Zeng J Bertolin AP Milligan JC Basu S Drury LS Deegan TD Fujisawa R Roberts EL Basier C Labib K Beale R Howell M Diffley JFX Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease Biochem J 2021 478 2445 2464 10.1042/bcj20210198 34198326 PMC8286829 · DOI
  121. [123]Zeng J Weissmann F Bertolin AP Posse V Canal B Ulferts R Wu M Harvey R Hussain S Milligan JC Roustan C Borg A McCoy L Drury LS Kjaer S McCauley J Howell M Beale R Diffley JFX Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase Biochem J 2021 478 2405 2423 10.1042/bcj20210201 34198322 PMC8286831 · DOI
  122. [124]Bye AP Hoepel W Mitchell JL Jégouic S Loureiro S Sage T Vidarsson G Nouta J Wuhrer M de Taeye S van Gils M Kriek N Cooper N Jones I den Dunnen J Gibbins JM Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets Blood 2021 138 1481 1489 10.1182/blood.2021011871 34315173 PMC8321687 · DOI
  123. [125]Milligan JC Zeisner TU Papageorgiou G Joshi D Soudy C Ulferts R Wu M Lim CT Tan KW Weissmann F Canal B Fujisawa R Deegan T Nagaraj H Bineva-Todd G Basier C Curran JF Howell M Beale R Labib K O'Reilly N Diffley JFX Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease Biochem J 2021 478 2499 2515 10.1042/bcj20210197 34198327 PMC8286836 · DOI
  124. [126]Lim CT Tan KW Wu M Ulferts R Armstrong LA Ozono E Drury LS Milligan JC Zeisner TU Zeng J Weissmann F Canal B Bineva-Todd G Howell M O'Reilly N Beale R Kulathu Y Labib K Diffley JFX Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease Biochem J 2021 478 2517 2531 10.1042/bcj20210244 34198325 PMC8286840 · DOI
  125. [127]Zhu W Chen CZ Gorshkov K Xu M Lo DC Zheng W RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery SLAS Discov 2020 25 1141 1151 10.1177/2472555220942123 32660307 PMC7684788 · DOI
  126. [128]Yan B Chu H Yang D Sze K-H Lai P-M Yuan S Shuai H Wang Y Kao RY-T Chan JF-W Yuen K-Y Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication Viruses 2019 11 73 10.3390/v11010073 PMC6357182 30654597 · DOI
  127. [129]Gur M Taka E Yilmaz SZ Kilinc C Aktas U Golcuk M Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states J Chem Phys 2020 153 075101 10.1063/5.0011141 32828084 · DOI
  128. [130]Allawadhi P Khurana A Allwadhi S Joshi K Packirisamy G Bharani KK Nanoceria as a possible agent for the management of COVID-19 Nano Today 2020 35 100982 10.1016/j.nantod.2020.100982 32952596 PMC7492057 · DOI
  129. [131]Allawadhi P Singh V Khurana A Khurana I Allwadhi S Kumar P Banothu AK Thalugula S Barani PJ Naik RR Bharani KK Silver nanoparticle based multifunctional approach for combating COVID-19 Sensors Intern 2021 2 100101 10.1016/j.sintl.2021.100101 PMC8169222 34766057 · DOI
  130. [132]Allawadhi P Singh V Khurana I Rawat PS Renushe AP Khurana A Navik U Allwadhi S Kumar Karlapudi S Banothu AK Bharani KK Decorin as a possible strategy for the amelioration of COVID-19 Medical Hypotheses 2021 152 110612 110612 10.1016/j.mehy.2021.110612 34098463 PMC8133800 · DOI
  131. [133]Khurana I Allawadhi P Khurana A Srivastava AK Navik U Banothu AK Bharani KK Can bilirubin nanomedicine become a hope for the management of COVID-19? Medical Hypotheses 2021 149 110534 10.1016/j.mehy.2021.110534 33640714 PMC7881296 · DOI
  132. [134]National Institutes of Health COVID-19 treatment guidelines panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines 2022 34003615

Cited by

Sorted by citations

Authors
Azali, M. A., Mohamed, S., Harun, A., Hussain, F. A., Shamsuddin, S., & Johan, M. F.
Affiliations
  • Universiti Sains Malaysia (MY)
  • Sultan Zainal Abidin University (MY)
Corresponding author
Johan, Muhammad Farid
ORCID
Venue
Journal of Genetic Engineering and Biotechnology
Publisher
Elsevier BV
Published
2022-12
Volume
20
Issue
1
Pages
98
ISSN
1687-157X (ISSN-L)
DOI
10.1186/s43141-022-00368-7
PMC
PMC9259773
OpenAlex
W4283827814
Cited by
13
References
1
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 2
FWCI
0.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Genetic Engineering and Biotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Universiti Sains Malaysia (1001/PPSP/8011025)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
Keywords
baculovirus expression system, SARS-CoV-2, COVID-19 diagnosis, COVID-19 treatment, recombinant protein, spike protein, receptor binding domain, non-structural proteins, drug repurposing, ACE2, recombinant antibodies, insect cell expression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review